Synthetic cannabinoids 2015: An update for pediatricians in clinical practice

被引:1
|
作者
Daniel Castellanos [1 ]
Leonard M Gralnik [1 ]
机构
[1] Department of Psychiatry and Behavioral Health, Herbert Wertheim College of Medicine, Florida International University
关键词
Synthetic; Cannabinoids; Youth; Children Adolescents;
D O I
暂无
中图分类号
R749.6 [中毒性精神障碍];
学科分类号
100205 ;
摘要
Synthetic cannabinoids are a group of substances in the world of designer drugs that have become increasingly popular over the past few years. Synthetic cannabinoids are a chemically diverse group of compounds functionally similar to THC. Since first appearing on the world market a few years ago these compounds have evolved rapidly. Newer more potent analogues have been developed. Identifying youth who abuse these substances can be difficult. Newer forms of consumption have also evolved. These products are now manufactured in products that look like natural cannabis resin and in liquid cartridges used in electronic cigarettes. Synthetic cannabinoids appear to be associated with potentially dangerous health effects that are more severe than that of marijuana. Some synthetic cannabinoid compounds have been associated with serious physical consequences, such as, seizures, myocardial infarction and renal damage. In addition, psychoactive effects, such as aggression, confusion, anxiety and psychosis have also been reported. The diagnosis remains primarily clinical with toxicological confirmation difficult due to manufacturers constantly developing new analogues to avoid detection. Pediatricians are urged to familiarize themselves with these drugs and the typical presentations of patients who use them.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 50 条
  • [1] Acute effects of synthetic cannabinoids: Update 2015
    Tournebize, Juliana
    Gibaja, Valerie
    Kahn, Jean-Pierre
    SUBSTANCE ABUSE, 2017, 38 (03) : 344 - 366
  • [2] Cannabinoids in Clinical Practice
    Elizabeth M. Williamson
    Fred J. Evans
    Drugs, 2000, 60 : 1303 - 1314
  • [3] Cannabinoids in clinical practice
    Williamson, EM
    Evans, FJ
    DRUGS, 2000, 60 (06) : 1303 - 1314
  • [4] Cannabinoids and CBD in clinical practice
    Braga, Patricia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [5] Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models
    Morales, Paula
    Reggio, Patricia H.
    CANNABINOIDS AND NEUROPSYCHIATRIC DISORDERS, 2021, 1264 : 47 - 65
  • [6] KDOQI CLINICAL PRACTICE GUIDELINE FOR HEMODIALYSIS ADEQUACY: 2015 UPDATE
    Daugirdas, John T.
    Depner, Thomas A.
    Inrig, Jula
    Mehrotra, Rajnish
    Rocco, Michael V.
    Suri, Rita S.
    Weiner, Daniel E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (05) : 884 - 930
  • [7] Pediatric Surgery Update with clinical Relevance for Pediatricians
    Ure, Benno
    MONATSSCHRIFT KINDERHEILKUNDE, 2019, 167 (11) : 969 - 970
  • [8] Identification and quantification of synthetic cannabinoids in "spice-like'' herbal mixtures: update of the German situation for the spring of 2015
    Langer, Nico
    Lindigkeit, Rainer
    Schiebel, Hans-Martin
    Papke, Uli
    Ernst, Ludger
    Beuerle, Till
    FORENSIC TOXICOLOGY, 2016, 34 (01) : 94 - 107
  • [9] Identification and quantification of synthetic cannabinoids in “spice-like” herbal mixtures: update of the German situation for the spring of 2015
    Nico Langer
    Rainer Lindigkeit
    Hans-Martin Schiebel
    Uli Papke
    Ludger Ernst
    Till Beuerle
    Forensic Toxicology, 2016, 34 : 94 - 107
  • [10] Pediatricians' perceptions of clinical practice guidelines
    Hendaus, Mohamed A.
    Alhammadi, Ahmed H.
    Razig, Eshraga A.
    Alnaimi, Lulwa
    JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2014, 7 : 349 - 353